Restructuring watch

Restructuring watch

Date Company Staff cuts Cash Years cash pre-cut Cash date Oper loss for 9 mos ended 9/30
10/8/08 Genmab (CSE:GEN) 16% to 540 $402.0 3.11 9/30/08 $97.0
Cuts primarily coming from R&D; says it plans to sharpens its focus on cancer
10/8/08 Nventa (TSX:NVN) 60% to 5 $5.9 0.55 10/1/08 $8.0
Reducing cash burn by 30%; seeking alternatives, including M&A or partners for lead compound HspE7, which has completed a Phase I trial to treat precancerous and cancerous lesions caused by HPV, and its preclinical compounds
10/10/08 Tripep (SSE:TPEP) (A) 66% to 2 $1.2 0.26 9/30/08 $3.5
Negotiating the sale of a portion of the rights to ChronSeal, a controlled-release gel formulation of hepatocyte growth factor (HGF) in Phase II testing for wound healing; planning to partner ChronVac-C, a DNA vaccine against HCV delivered using MedPulser electroporation platform that is in Phase I/II testing to treat HCV infection
10/16/08 Cell Genesys (NASDAQ:CEGE) 75% to ~72 $148.1 2.40 9/30/08 $46.3
Exploring strategic alternatives, including a merger or

Read the full 2064 word article

How to gain access

Continue reading with a
two-week free trial.